Interferon-alpha (IFNα) can induce major cytogenetic responses in 30 to 40% of patients
with chronic myelogenous leukaemia (CML) and up to 50% when combined with cytarabine …

In 1983 Talpaz et al.(43) for the first time demonstrated the efficacy of interferon-alpha (IFN-
alpha) for the treatment of patients with chronic myelogenous leukemia (CML). This …

Interferon-A (IFN-A) is an effective agent in the treatment of chronic myelogenous leukemia
(CML). Hematologic remissions occur in the majority of patients with newly diagnosed …

PURPOSE: To provide a status report on the use of interferon (IFN)-a in patients with chronic
myelogenous leukemia (CML). DATA SOURCES: Data on IFN-a therapy for CML collected …

In a series of studies spanning 14 years, investigators from MD Anderson Cancer Center
(Houston, TX) documented the activity of interferon-alfa (IFN-alpha) in chronic myelogenous …

Until the 1980's chronic myeloid leukaemia (CML) was treated mainly with the cytotoxic
drugs, busulphan and hydroxyurea which controlled but did not cure the disease. Only …

Interferon-α may be better than cytotoxic drugs in the long-term management of patients with
chronic myeloid leukaemia (CML) in chronic phase. To test this possibility 587 patients with …

The place of alpha interferon (IFN) therapy in the treatment of chronic myeloid leukaemia
(CML) is under intensive investigation at present. It is now established that as a single agent …

Chronic myelogenous leukemia (CML) is a lethal malignancy involving the hematopoietic
stem cell. The disease is marked by the Philadelphia chromosome (Ph), a balanced …

Newly diagnosed chronic myelogenous leukaemia (CML) patients (n= 65) were treated with
interferon (IFN)‐α2b (5× 106 IU/d sc) combined with monthly courses of cytarabine (20 mg/d …